Trial Profile
Phase III long-term study of TAK-536CCB in patients with grade I or II essential hypertension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Amlodipine/azilsartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Takeda
- 09 May 2013 New trial record